Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/12639
Full metadata record
DC FieldValueLanguage
dc.rights.licenseopenAccess-
dc.contributor.authorMuric, Nemanja-
dc.contributor.authorArsenijevic, Nebojsa-
dc.contributor.authorBorovcanin, Milica-
dc.date.accessioned2021-04-20T21:21:26Z-
dc.date.available2021-04-20T21:21:26Z-
dc.date.issued2020-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/12639-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceFrontiers in Psychiatry-
dc.titleChlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment-
dc.typearticle-
dc.identifier.doi10.3389/fpsyt.2020.612347-
dc.identifier.scopus2-s2.0-85099047453-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

476

Downloads(s)

22

Files in This Item:
File Description SizeFormat 
10.3389-fpsyt.2020.612347.pdf163.61 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons